Clinical Trials Logo

Gastroesophageal Varices clinical trials

View clinical trials related to Gastroesophageal Varices.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT04543643 Not yet recruiting - Clinical trials for Gastroesophageal Varices

Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis

CABER
Start date: November 1, 2021
Phase: Phase 3
Study type: Interventional

Carvedilol has been shown to be more potent in decreasing portal hypertension to propranolol. A lot of studies have shown that the imbalance of flora and the progress of portal hypertension are mutually causal. Berberine can regulate the intestinal flora.In this study, we evaluated the effect of carvedilol and berberine on reducing portal vein pressure by observing the changes of endoscopy,endoscopic ultrasonography and intestinal flora.

NCT ID: NCT04527666 Not yet recruiting - Clinical trials for Myeloproliferative Neoplasm

Anticoagulation in Gastroesophageal Varices and JAK2 Mutation

Start date: October 1, 2020
Phase:
Study type: Observational

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. The aim of this study is to evaluate the efficacy of anticoagulation in patients with JAK2 mutation and gastroesophageal varices.

NCT ID: NCT04525768 Not yet recruiting - Portal Hypertension Clinical Trials

Gastroesophageal Varices in Cavernoma

Start date: October 1, 2020
Phase:
Study type: Observational

Myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis, may lead to gastroesophageal varices. The quality of life, morbidity, and mortality of MPN patients mainly depend on disease-related symptoms, thromboembolic and hemorrhagic complications. Previous studies have shown that JAK2 V617F has a prominent role in vascular risk and MPN-associated gastroesophageal varices. Portal vein thrombosis and portal cavernoma frequently occur in the MPN population and the management of gastroesophageal varices in these patients are sometimes technically difficult. The aim of this study is to investigate the the characteristics of patients with gastroesophageal varices and portal caver cavernoma with or without JAK2 mutation.

NCT ID: NCT04524650 Not yet recruiting - Colorectal Cancer Clinical Trials

Early Diagnosis of Oxaliplatin-induced Portal Hypertension

Start date: August 31, 2020
Phase:
Study type: Observational

Oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. However, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. The pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of hepatic sinusoidal injury. Oxaliplatin-induced sinusoidal injury can persist for more than 1 year after the completion of chemotherapy, and the increase in splenic volume may be a predictor of irreversible sinusoidal damage. In this current study, the investigators aim to evaluate the values of potential biomarkers in diagnosing patients with oxaliplatin-induced gastroesophageal varices after colorectal cancer surgery.

NCT ID: NCT03729921 Not yet recruiting - Liver Cirrhosis Clinical Trials

Gastric Variceal Ligation Versus Gastric Variceal Obturation for Secondary Prophylaxis of Gastric Varices

Start date: November 2018
Phase: N/A
Study type: Interventional

The investigators establish a randomized controlled clinical trial, comparing the efficacy and prognosis of GVL and GVO in secondary prevention of GVs, especially in patients with portosystemic shunting, and exploring the endoscopic treatment selection of different types of GVs. Outcome expectations: Compared with glue injection, endoscopic ligation for secondary prevention of gastric varices is safe and effective, especially in patients with portosystemic shunting.